Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.56 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.52 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.52 |
| ▸ | TK1 | P04183 | 1/20 | 0.43 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.41 |
| ▸ | TK2 | O00142 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12240330 | 1.00 | PYGM (0.56) | PYGMP2RY6P2RY14TK1DNPH1 | |
| SCHEMBL2614693 | 1.00 | PYGM (0.56) | PYGMP2RY6P2RY14TK1DNPH1 | |
| SCHEMBL14712700 | 0.92 | PYGM (0.56) | PYGMP2RY6P2RY14TK1DNPH1 | |
| SCHEMBL8588339 | 0.92 | PYGM (0.56) | PYGMP2RY6P2RY14TK1DNPH1 | |
| SCHEMBL20072701 | 0.88 | TK2 (0.47) | PYGMTK2 | |
| SCHEMBL2614692 | 0.88 | PYGM (0.56) | PYGMP2RY6P2RY14DNPH1TK2 | |
| SCHEMBL12240327 | 0.88 | PYGM (0.56) | PYGMP2RY6P2RY14DNPH1TK2 | |
| SCHEMBL1699665 | 0.88 | PYGM (0.56) | PYGMP2RY6P2RY14DNPH1TK2 | |
| SCHEMBL26872396 | 0.81 | SLC28A1 (0.56) | P2RY6P2RY14 | |
| SCHEMBL15336921 | 0.81 | PYGM (0.61) | PYGMP2RY6P2RY14TK1DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143631-A1 | LIPID FORMULATION | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-05-25 | — | — | US | disclosed |
| US-8563710-B2 | Modified oligonucleotide and its preparation and application | BIOMICS BIOTECHNOLOGIES CO., LTD. (CN) | 2013-10-22 | — | — | US | disclosed |
| US-20120088815-A1 | Modified Oligonucleotide and Its Preparation and Application | BIOMICS BIOTECHNOLOGIES CO. LTD (CN) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088815-A1 | Modified Oligonucleotide and Its Preparation and Application | UNG, NSUN2, UPF1 | PYGM 2272/4885P2RY6 1545/4885P2RY14 2949/4885 |
| US-20170143631-A1 | LIPID FORMULATION | CETP, LIPA, SGMS1 | PYGM 4343/4885P2RY6 3813/4885P2RY14 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.